Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022GlobeNewsWire • 11/03/22
Wave Life Sciences (WVE) Soars 13.8%: Is Further Upside Left in the Stock?Zacks Investment Research • 10/17/22
MDA Breakout Stocks Week 40 - October 2022: Short-Term Picks To Give You An EdgeSeeking Alpha • 10/03/22
Wave Life Sciences to Highlight Advancements from PRISM Platform at Upcoming Scientific CongressesGlobeNewsWire • 10/03/22
Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor EventGlobeNewsWire • 09/28/22
Wave Life Sciences to Present at Chardan's 6th Annual Genetic Medicines ConferenceGlobeNewsWire • 09/27/22
MDA Breakout Stocks Week 39 - September 2022: Short-Term Picks To Give You An EdgeSeeking Alpha • 09/26/22
Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington's DiseaseGlobeNewsWire • 09/20/22
Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022GlobeNewsWire • 09/16/22
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/11/22
Wave Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 08/11/22
Wave Life Sciences to Webcast Conference Call of Second Quarter 2022 Financial Results on August 11, 2022GlobeNewsWire • 07/28/22
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/12/22
Wave Life Sciences Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 05/12/22
Wave Life Sciences to Webcast Conference Call of First Quarter 2022 Financial Results on May 12, 2022GlobeNewsWire • 05/05/22
Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTDGlobeNewsWire • 04/25/22
Wave Life Sciences to Present at Chardan's 6th Annual Genetic Medicines and Cell Therapy Manufacturing SummitGlobeNewsWire • 04/19/22
Wave Life Sciences Jump As Low Doses of WVE-004 Lowers Disease Biomarker In Neurological IndicationsBenzinga • 04/04/22
Wave Life Sciences Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study Driven by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004GlobeNewsWire • 04/04/22